Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in ...

Retrieved on: 2020-12-22 10:18:45

Tags for this article:

Respiratory diseases

Medical specialties

Sarbecovirus

Medicine

Bat virome

Severe acute respiratory syndrome

COVID-19

Acute respiratory distress syndrome

Respiratory distress syndrome

COVID-19 drug repurposing research

Cytokine storm

Paris

Click the tags to see associated articles and topics

Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in .... View article details on hiswai:

Excerpt

Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today ...

Article found on: www.galvnews.com

View Original Article